6-(5-Chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo[3,4-b]pyrazin-5-one
[CAS# 43200-81-3]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyrazines
• Name: 6-(5-Chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo[3,4-b]pyrazin-5-one
• Synonyms: 43200-81-3
• Molecular Formula: C₁₁H₇ClN₄O₂
• Molecular Weight: 262.65
• CAS Registry Number: 43200-81-3
• EC Number: 256-139-4
• SMILES: C1=CC(=NC=C1Cl)N2C(C3=NC=CN=C3C2=O)O

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302-H319
• Safety Statements: P264-P264+P265-P270-P280-P301+P317-P305+P351+P338-P330-P337+P317-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Eye irritation	Eye Irrit.	2	H319
Acute toxicity	Acute Tox.	4	H302
Acute toxicity	Acute Tox.	4	H312
Acute toxicity	Acute Tox.	4	H332

Discovery and Applications

6-(5-Chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo[3,4-b]pyrazin-5-one is a chemical substance notable for its unique structure and potential applications in medicinal chemistry. The compound belongs to a class of heterocyclic compounds, characterized by the presence of a pyrrolo[3,4-b]pyrazine ring system. This structure contributes to its distinctive chemical and biological properties, making it an interesting subject for pharmaceutical research.

The discovery of this compound is rooted in the search for new pharmacological agents with improved efficacy and safety profiles. Researchers and chemists have long been interested in heterocyclic compounds due to their diverse biological activities. The specific compound in question was identified through a series of synthetic and screening efforts aimed at developing novel molecules with potential therapeutic applications. Its synthesis involves the combination of a chloro-pyridyl group with a pyrrolo[3,4-b]pyrazine ring, which introduces both electron-donating and electron-withdrawing groups into the molecule.

The primary application of 6-(5-Chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo[3,4-b]pyrazin-5-one lies in its potential as a pharmaceutical agent. The compound has shown promise in preclinical studies for various therapeutic applications. One notable area of research is its potential use as an antimicrobial or antiviral agent. The unique structure of the compound, which includes both a pyridyl group and a pyrrolo[3,4-b]pyrazine ring, may confer activity against specific pathogens or viruses. Studies have explored its efficacy in inhibiting the growth of bacteria and viruses, offering insights into its potential as a new therapeutic agent.

In addition to its antimicrobial and antiviral potential, the compound has been investigated for its possible applications in the treatment of cancer. The presence of the hydroxyl group and the specific arrangement of heterocyclic rings could contribute to its ability to interact with biological targets involved in cancer progression. Research into the compound's mechanism of action and its effectiveness in preclinical cancer models is ongoing, with the aim of identifying any potential therapeutic benefits.

The synthesis of 6-(5-Chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo[3,4-b]pyrazin-5-one involves several chemical steps, including the formation of the heterocyclic ring system and the introduction of functional groups. This process requires careful control of reaction conditions to achieve the desired product with high purity. The compound's synthesis and characterization are critical for its development as a pharmaceutical agent.

In summary, 6-(5-Chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo[3,4-b]pyrazin-5-one represents a promising chemical substance with potential applications in medicine. Its unique structure and preliminary research suggest possible uses in antimicrobial, antiviral, and anticancer therapies. Ongoing research and development efforts are focused on exploring its full range of biological activities and therapeutic potential.

References

2003. Zopiclone. Pharmaceutical Substances.
URL: https://pharmaceutical-substances.thieme.com/ps/search-results?docUri=KD-26-0017


2006. Eszopiclone. Pharmaceutical Substances.
URL: https://pharmaceutical-substances.thieme.com/ps/search-results?docUri=KD-05-0071


2007. Determination of zopiclone in urine by gas chromatography-mass spectrometry. Journal of Analytical Chemistry, 62(5).
DOI: 10.1134/s1061934807050115